Charles River conducts contract studies to assess therapeutic agents designed to interfere with diet-induced obesity (DIO). Our offerings provide a flexible platform for the assessment of physiologic changes and the attendant biomarkers associated with DIO.
A typical study measures body weight, food intake, blood glucose and glucose/insulin tolerance over a period of 2-4 weeks. A terminal blood sample is taken for the estimation of biomarkers such as plasma lipids, insulin, glucagon, adipocytokines and other hormones. However, we can combine your choice of species, strain, diet and analytical parameters in order to customize studies to suit your unique needs.